Page 6 - CCfV-Annual-Report-2013-14

Research Highlights Evaluation Group In 2013 there were 821 participants enrolled in 23 diferent studies The Clinical Trials Research Center requiring 1991 visits and 1273 (CTRC) is the centre of vaccine follow up phone calls. In addition, evaluation at CCfV. more than 1500 infuenza immunization surveys were analyzed. Investigators and staf provide expertise in the development and implementation of studies ranging from frst-in-human to post licensure trials, monitoring and evaluation. Vaccine companies sponsoring studies in Te CTRC team includes expertise in clinical 2013 included: infectious diseases, epidemiology, statistics, data • Folia Biotech management and analysis, project management, • GlaxoSmithKline nursing and communications. Both the safety • Immunovaccine and immunogenicity of candidate vaccines are • Merck studied, as well as the feld efectiveness of vaccines • Novartis and their efects on disease burden, vaccine • Pan-Provincial Vaccine Enterprise compliance, and public acceptance. (PREVENT) • Pfzer Evaluative research in 2013 focused on a • Sanof Pasteur first-in-humans RSV vaccine study, vaccines in pregnancy (pertussis and group B streptococcus), severe outcomes with influenza Public-sector organizations funding clinical infection leading to hospitalization, quadrivalent research through grants or contracts have influenza vaccines in young children, rotavirus included the following: and Clostridium difficile vaccines, zoster (shingles) vaccine in older persons with immune • Canadian Institutes of Health Research compromise, vaccine safety, and meningococcal • Public Health Agency of Canada infection in young children and young adults. • The Michael Smith Foundation 4 Canadian Center for Vaccinology